share_log

Allmed Medical Products' (SZSE:002950) Shareholders Have More To Worry About Than Only Soft Earnings

Allmed Medical Products' (SZSE:002950) Shareholders Have More To Worry About Than Only Soft Earnings

Allmed Medical Products(SZSE:002950)的股東們需要擔心的不僅僅是疲軟的收益
Simply Wall St ·  2022/05/07 10:18

Allmed Medical Products Co., Ltd's (SZSE:002950) stock rose after its recent weak earnings report. Sometimes, shareholders are willing to ignore soft numbers with the hope that they will improve, but our analysis suggests this is unlikely for Allmed Medical Products.

艾爾梅德醫療產品有限公司(SZSE:002950)在近期發佈疲弱的收益報告後,股價上漲。有時,股東願意忽視疲軟的數據,希望它們會有所改善,但我們的分析表明,對於Allmed Medical Products來説,這不太可能。

See our latest analysis for Allmed Medical Products

查看我們對Allmed醫療產品的最新分析

SZSE:002950 Earnings and Revenue History May 7th 2022
深交所:002950年度盈利及收入歷史2022年5月7日

How Do Unusual Items Influence Profit?

不尋常的項目如何影響利潤?

Importantly, our data indicates that Allmed Medical Products' profit received a boost of CN¥80m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

重要的是,我們的數據顯示,在過去的一年裏,Allmed醫療產品的利潤在異常項目上增加了8000萬元人民幣。我們不能否認,更高的利潤通常會讓我們保持樂觀,但如果利潤是可持續的,我們更願意這樣做。我們對全球大多數上市公司進行了統計,不尋常的項目在性質上是一次性的,這是非常常見的。畢竟,這正是會計術語所暗示的。假設這些不同尋常的項目在本年度不會再次出現,我們因此預計明年的利潤會更弱(也就是説,在沒有業務增長的情況下)。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Allmed Medical Products.

注:我們總是建議投資者檢查資產負債表的實力。點擊此處查看我們對Allmed醫療產品的資產負債表分析。

Our Take On Allmed Medical Products' Profit Performance

我們對Allmed醫療產品公司利潤表現的看法

Arguably, Allmed Medical Products' statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Allmed Medical Products' statutory profits are better than its underlying earnings power. But the good news is that its EPS growth over the last three years has been very impressive. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Allmed Medical Products, you'd also look into what risks it is currently facing. At Simply Wall St, we found 2 warning signs for Allmed Medical Products and we think they deserve your attention.

可以説,Allmed Medical Products的法定收益被不尋常的提高利潤的項目扭曲了。正因為如此,我們認為Allmed Medical Products的法定利潤可能好於其潛在的盈利能力。但好消息是,該公司過去三年的每股收益增長令人印象深刻。本文的目的是評估我們可以在多大程度上依賴法定收益來反映公司的潛力,但還有很多東西需要考慮。如果你想更深入地研究Allmed醫療產品,你還可以看看它目前面臨的風險。在Simply Wall St.,我們發現了兩個Allmed醫療產品的警告標誌,我們認為它們值得您關注。

This note has only looked at a single factor that sheds light on the nature of Allmed Medical Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

這份報告只關注了一個因素,它揭示了Allmed醫療產品公司利潤的本質。但如果你有能力將注意力集中在細枝末節上,總會有更多的東西需要發現。例如,許多人認為高股本回報率是有利的商業經濟指標,而另一些人則喜歡“跟着錢走”,尋找內部人士正在買入的股票。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論